JP2023518635A5 - - Google Patents
Info
- Publication number
- JP2023518635A5 JP2023518635A5 JP2022538393A JP2022538393A JP2023518635A5 JP 2023518635 A5 JP2023518635 A5 JP 2023518635A5 JP 2022538393 A JP2022538393 A JP 2022538393A JP 2022538393 A JP2022538393 A JP 2022538393A JP 2023518635 A5 JP2023518635 A5 JP 2023518635A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- brain
- nac
- analogue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949640P | 2019-12-18 | 2019-12-18 | |
| US62/949,640 | 2019-12-18 | ||
| US202062970254P | 2020-02-05 | 2020-02-05 | |
| US62/970,254 | 2020-02-05 | ||
| PCT/US2020/066179 WO2021127541A1 (en) | 2019-12-18 | 2020-12-18 | Methods of treating brain disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518635A JP2023518635A (ja) | 2023-05-08 |
| JP2023518635A5 true JP2023518635A5 (cg-RX-API-DMAC7.html) | 2024-07-03 |
Family
ID=76437600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538393A Pending JP2023518635A (ja) | 2019-12-18 | 2020-12-18 | 脳障害を処置する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US12090130B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4076425A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023518635A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115484945A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020407239B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3165422A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021127541A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210128509A1 (en) * | 2019-11-04 | 2021-05-06 | Neuronasal, Inc. | Use of magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of n-acetylcysteine |
| CA3165422A1 (en) * | 2019-12-18 | 2021-06-24 | Neuronasal, Inc. | Methods of treating brain disorders |
| WO2022072318A1 (en) * | 2020-10-01 | 2022-04-07 | Lyra Therapeutics, Inc. | Osmotic drug delivery implants |
| WO2022067232A1 (en) * | 2020-09-28 | 2022-03-31 | Commercial Automation, Llc | Food product storage and vending kiosk |
| US12594254B2 (en) * | 2022-02-07 | 2026-04-07 | Neuronasal, Inc. | Intranasal administration of n-acetylcysteine and uses thereof |
| US20260165992A1 (en) * | 2024-12-13 | 2026-06-18 | Neuronasal, Inc. | Treatment of central nervous system diseases with n-acetylcysteine and glucagon-like peptide-1 receptor agonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2606053A1 (en) | 2005-04-21 | 2006-11-02 | Glenn Goldstein | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
| WO2008131059A2 (en) | 2007-04-17 | 2008-10-30 | Codman & Shurtleff, Inc. | Intranasally administering curcumin in a bolus of helium gas to treat alzheimer's disease |
| WO2013163545A1 (en) | 2012-04-26 | 2013-10-31 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of disease and injury |
| US20160058726A1 (en) | 2013-04-16 | 2016-03-03 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of brain injury |
| JP7074663B6 (ja) * | 2015-05-28 | 2022-08-01 | ベイラー カレッジ オブ メディスン | グルタチオンレベルを改善するためのn-アセチルシステイン及びグリシンの補給の効果 |
| EP3618824A4 (en) * | 2017-05-02 | 2021-06-23 | Neuronasal, LLC | USE OF N-ACETYLCYSTONE FOR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| EP3700525A4 (en) * | 2017-10-27 | 2021-08-25 | Beyond Barriers Therapeutics, Inc. | IMPROVED PROVISION OF ANTIOXIDANTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES WITH OXIDATIVE STRESS |
| CA3165422A1 (en) * | 2019-12-18 | 2021-06-24 | Neuronasal, Inc. | Methods of treating brain disorders |
-
2020
- 2020-12-18 CA CA3165422A patent/CA3165422A1/en active Pending
- 2020-12-18 JP JP2022538393A patent/JP2023518635A/ja active Pending
- 2020-12-18 AU AU2020407239A patent/AU2020407239B2/en active Active
- 2020-12-18 US US17/127,075 patent/US12090130B2/en active Active
- 2020-12-18 EP EP20901612.0A patent/EP4076425A1/en not_active Withdrawn
- 2020-12-18 WO PCT/US2020/066179 patent/WO2021127541A1/en not_active Ceased
- 2020-12-18 CN CN202080096923.5A patent/CN115484945A/zh active Pending
-
2024
- 2024-08-02 US US18/792,836 patent/US12414929B2/en active Active
-
2025
- 2025-09-15 US US19/328,413 patent/US20260007626A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2838529C (en) | Methods of treatment | |
| JP2023507094A5 (cg-RX-API-DMAC7.html) | ||
| JP2023500360A5 (cg-RX-API-DMAC7.html) | ||
| JP2019520361A5 (cg-RX-API-DMAC7.html) | ||
| JP2008536546A5 (cg-RX-API-DMAC7.html) | ||
| RU2005135335A (ru) | Назальные фармацевтические композиции и способы их применения | |
| FI4106757T3 (fi) | Neutrofiilien elastaasin inhibiittori alvelestaattia sisältäviä menetelmiä alfa-1-antitrypsiinipuutoksen välittämän hengityselintaudin hoitamiseksi | |
| JP2014516081A5 (cg-RX-API-DMAC7.html) | ||
| BR0311558A (pt) | composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica | |
| JP2021152060A (ja) | アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法 | |
| HRP20192111T1 (hr) | Liječenje poremećaja središnjeg živčanog sustava intranazalnom primjenom imunoglobulina g | |
| EA022840B1 (ru) | Фармацевтическая композиция, набор, их применение и способ профилактики и лечения симптома, состояния или заболевания, связанного с инфекцией вируса гриппа | |
| US20230263725A1 (en) | Intranasal administration of an antioxidant compound for treating coronavirus infection | |
| JP2023500032A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0409434A (pt) | formulações farmacêuticas nasais e métodos para usar as mesmas | |
| EP1201236A4 (en) | MEDICAL COMPOSITIONS FOR PREVENTING THE TREATMENT OF VIRAL MYOCASCHITIS | |
| RU2011101771A (ru) | Педиатрические композиции для лечения рассеянного склероза | |
| JP2020531586A5 (cg-RX-API-DMAC7.html) | ||
| JP2023520703A5 (cg-RX-API-DMAC7.html) | ||
| JP2023520929A5 (cg-RX-API-DMAC7.html) | ||
| CN108472375A (zh) | 中重度流感的治疗方法 | |
| JP2023539847A5 (cg-RX-API-DMAC7.html) | ||
| EA202190724A1 (ru) | Препарат на основе кетамина для лечения депрессий путём ингаляций | |
| US12611389B1 (en) | Compositions and methods to reduce or eliminate nasal biofilms and mucus barriers allowing sodium pyruvate to increase the synthesis of nitric oxide and eliminate nasal infections and their toxins that cause lung, nerve and brain damage | |
| Pooja et al. | A Review: Nasopulmonary Drug Delivery System |